According to GlobalData’s medical device pipeline database, 26 Cardiac Markers Rapid Tests & POC devices are in various stages of development globally. GlobalData’s report Cardiac Markers Rapid Tests & POC provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.

Smarter leaders trust GlobalData

Of these devices, six are in active development, while the remaining 20 are in an inactive stage of development. There are five products in the early stages of development, and the remaining one is in the late stages of development.

In Vitro Diagnostics (IVD) include reagents, instruments and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. Rapid diagnostic tests are simple to perform, ready to use, accurate, economic and for infield use suggested for individuals suspected with any indication. These tests yield rapid results when compared to laboratory based tests. For the purpose of this model, we have considered tests that yield results within 30 minutes of receipt of sample. These tests are qualitative and are performed independently without the aid of any analyzer or external device. POC tests are a part of rapid diagnostic tests and are performed in close proximity to the patient which can be qualitative, quantitative and qualitative/quantitative. Quantitative POC tests are performed with the aid of an analyzer. It includes troponin rapid tests & POC, brain natriuretic peptide (BNP) rapid tests & POC, and other cardiac markers rapid tests & POC.

Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.

Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Cardiac Markers Rapid Tests & POC pipeline devices are all expected to be approved within the next ten years.

Currently, private organizations, public entities and institutions are working on the development of Cardiac Markers Rapid Tests & POC devices. Overall, most of these Cardiac Markers Rapid Tests & POC pipeline devices are being developed by private entities.

Key players involved in the active development of Cardiac Markers Rapid Tests & POC include Upstream Medical Technologies, Boditech Med, Eachy Biopharmaceuticals, Maxim Biomedical, MiCo BioMed, MyMD Pharmaceuticals, Nanomix, Nanospot.ai, Novartis and Ohmx.

For a complete picture of the developmental pipeline for Cardiac Markers Rapid Tests & POC devices, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.